Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening

Abstract

Fecal microbiota transplantation (FMT) by manual preparation has been applied to treat diseases for thousands of years. However, this method still endures safety risks and challenges the psychological endurance and acceptance of doctors, patients and donors. Population evidence showed the washed microbiota preparation with microfiltration based on an automatic purification system followed by repeated centrifugation plus suspension for three times significantly reduced FMT-related adverse events. This washing preparation makes delivering a precise dose of the enriched microbiota feasible, instead of using the weight of stool. Intraperitoneal injection in mice with the fecal microbiota supernatant obtained after repeated centrifugation plus suspension for three times induced less toxic reaction than that by the first centrifugation following the microfiltration. The toxic reactions that include death, the change in the level of peripheral white blood cells, and the proliferation of germinal center in secondary lymphoid follicles in spleen were noted. The metagenomic next-generation sequencing (NGS) indicated the increasing types and amount of viruses could be washed out during the washing process. Metabolomics analysis indicated metabolites with pro-inflammatory effects in the fecal microbiota supernatant such as leukotriene B4, corticosterone, and prostaglandin G2 could be removed by repeated washing. Near-infrared absorption spectroscopy could be served as a rapid detection method to control the quality of the washingprocess. In conclusion, this study for the first time provides evidence linking clinical findings and animal experiments to support that washed microbiota transplantation (WMT) is safer, more precise and more quality-controllable than the crude FMT by manual.

Key words： fecal microbiota transplantation; washed microbiota transplantation; adverse event; safety; infection; virus; metabolomics; spectroscopy; transplant

References

1 Aboul-Ata AA, Vitti A, Nuzzaci M, El-Attar AK, Piazzolla G, Tortorella C, Harandi AM, Olson O, Wright SA, Piazzolla P (2014) Plantbased vaccines: novel and low-cost possible route for Mediterranean innovative vaccination strategies. Adv Virus Res 89:1–37

2 Afarideh M, Behdadnia A, Noshad S, Mirmiranpour H, Mousavizadeh M, Khajeh E, Rad MV, Mazaheri T, Nakhjavani M, Esteghamati A (2015) Association of peripheral 5-hydroxyindole-3-acetic acid, a serotonin derivative, with metabolic syndrome and low-grade inflammation. Endocr Pract 21:711–718

3 Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35:284–292

4 Alhouayek M, Masquelier J,Cani PD, Lambert DM, Muccioli GG (2013) Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc Natl Acad Sci U S A 110:17558–17563

5 Allegretti JR, Mullish BH, Kelly C, Fischer M (2019) The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet 394:420–431

6 Austenaa LM, Carlsen H, Hollung K, Blomhoff HK, Blomhoff R (2009) Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NFkappaB reporter mice. J Nutr Biochem 20:726–734

7 Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T (2017) Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66:1727–1738

8 Bigagli E, Cinci L, Paccosi S, Parenti A, D’Ambrosio M, Luceri C (2017) Nutritionally relevant concentrations of resveratrol and hydroxytyrosol mitigate oxidative burst of human granulocytes and monocytes and the production of pro-inflammatory mediators in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol 43:147–155

9 Boltana S, Sanhueza N, Donoso A,Aguilar A, Crespo D, Vergara D, Arriagada G, Morales-Lange B, Mercado L,Rey S (2018) The expression of TRPV channels, prostaglandin E2 and proinflammatory cytokines during behavioural fever in fish. Brain Behav Immun 71:169–181

10 Brandt LJ (2012) Editorial commentary: fecal microbiota transplantation: patient and physician attitudes. Clin Infect Dis 55:1659–1660

11 Cai J, Peng Y, Chen T, Liao H, Zhang L, Chen Q, He Y, Wu P, Xie T, Pan Q (2016) Chloral hydrate treatment induced apoptosis of macrophages via Fas signaling pathway. Med Sci Monit 22:4836–4843

12 Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, Sokol H, Arkkila P,Pintus C, Hart A (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66:569–580

13 Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP (2019) International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 68(12):2111–2121

14 Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM (2016) Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62:908–914

15 Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P,Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C (2019) Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321:156–164

16 Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, Xu H, Xiang J, He Z, Zhang T (2015) Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med 13:298

17 Cui B, Li P, Xu L, Peng Z, Xiang J, He Z, Zhang T, Ji G, Nie Y, Wu K (2016) Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes 7:323–328

18 DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL (2019) Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 381:2043–2050

19 Ding X, Li Q, Li P,Zhang T,Cui B, Ji G, Lu X, Zhang F(2019) Longterm safety and efficacy of fecal microbiota transplant in active ulcerative colitis. Drug Saf 42:869–880

20 He Z, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G (2017) Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass. Sci Rep 7:4753

21 Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, Zhou YL, Yao F, Nie YQ, Zhou YJ (2019) Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. J Dig Dis 20:401–408

22 Jilma-Stohlawetz P, Kliegel T,Kantner-Schlifke I, Strasser-Marsik C,Mayr FB, Jilma B (2017) Upregulation of cytokine mRNA in circulating leukocytes during human endotoxemia. Eur Cytokine Netw 28:19–26

23 Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, Khoruts A, Geis E, Maldonado J, McDonough-Means S(2017) Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5:10

24 Kim YS, Park ZY, Kim SY, Jeong E, Lee JY (2009) Alteration of Tolllike receptor 4 activation by 4-hydroxy-2-nonenal mediated by the suppression of receptor homodimerization. Chem Biol Interact 182:59–66

25 Kim SR, Jung YR, Kim DH, An HJ, Kim MK, Kim ND, Chung HY (2014) Caffeic acid regulates LPS-induced NF-kappaB activation through NIK/IKK and c-Src/ERK signaling pathways in endothelial cells. Arch Pharm Res 37:539–547

26 Konig J, Siebenhaar A, Hogenauer C, Arkkila P,Nieuwdorp M, Noren T,Ponsioen CY, Rosien U, Rossen NG, Satokari R (2017) Consensus report: faecal microbiota transfer—clinical applications and procedures. Aliment Pharmacol Ther 45:222–239

27 Kurhaluk N, Zaitseva OV, Sliuta A, Kyriienko S, Winklewski PJ (2018) Melatonin diminishes oxidative stress in plasma, retains erythrocyte resistance and restores white blood cell count after low dose lipopolysaccharide exposure in mice. Gen Physiol Biophys 37:571–580

28 Kwon SY, Ro M, Kim JH (2019) Mediatory roles of leukotriene B4 receptors in LPS-induced endotoxic shock. Sci Rep 9:5936

29 Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760

30 Lin L, Chen X, Zhou Q, Huang P, Jiang S, Wang H, Deng Y (2019) Synaptic structure and alterations in the hippocampus in neonatal rats exposed to lipopolysaccharide. Neurosci Lett 709:134364

31 Liu Y, Fang S, Li X, Feng J, Du J, Guo L, Su Y, Zhou J, Ding G, Bai Y (2017) Aspirin inhibits LPS-induced macrophage activation via the NF-kappaB pathway. Sci Rep 7:11549

32 Lu J, Huang G, Wang Z, Zhuang S, Xu L, Song B, Xiong Y, Guan S (2013) Tyrosol exhibits negative regulatory effects on LPS response and endotoxemia. Food Chem Toxicol 62:172–178

33 Ma Y,Yang J, Cui B, Xu H, Xiao C, Zhang F (2017) How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study. BMC Med Ethics 18:39

34 Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V, Salminen K, Seppala M, Mattila PS (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142:490–496

35 McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66:987–994

36 McSweeney B, Allegretti JR, Fischer M, Xu H,Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL (2019) In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes.https://doi.org/10.1080/19490976.2019.1611153

37 Metsola J, Maksimow M, Ojaniemi M, Metsola H, Marttila-Ichihara F, Vuolteenaho R, Yegutkin GG, Salmi M, Hallman M, Jalkanen S (2014) Postnatal development and LPS responsiveness of pulmonary adenosine receptor expression and of adenosinemetabolizing enzymes in mice. Pediatr Res 76:515–521

38 Miller S, Naccache SN, Samayoa E, Messacar K, Arevalo S, Federman S, Stryke D, Pham E, Fung B, Bolosky WJ (2019) Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. Genome Res 29:831–842

39 Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z,Reinisch W (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149(102–109):e106

40 Ng SC, Kamm MA, Yeoh YK, Chan PKS, Zuo T, Tang W, Sood A, Andoh A, Ohmiya N, Zhou Y(2019) Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). Gut 69(1):83–91

41 Nilius B, Owsianik G (2011) The transient receptor potential family of ion channels. Genome Biol 12:218

42 Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebocontrolled trial. Lancet 389:1218–1228

43 Park L, Mone A, Price JC, Tzimas D, Hirsh J, Poles MA, Malter L, Chen LA (2017) Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance. Ann Gastroenterol 30:83–88

44 Pilgrim MJ, Kasman L, Grewal J, Bruorton ME, Werner P, London L, London SD (2007) A focused salivary gland infection with attenuated MCMV: an animal model with prevention of pathology associated with systemic MCMV infection. Exp Mol Pathol 82:269–279

45 Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, Zhang F, Wu D (2018) Treating steroid refractory intestinal acute graft-vs.-host disease with fecal microbiota transplantation: a pilot study. Front Immunol 9:2195

46 Satokari R,Mattila E, Kainulainen V,Arkkila PE (2015) Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection–an observational cohort study. Aliment Pharmacol Ther 41:46–53

47 Sood A, Mahajan R, Juyal G, Midha V, Grewal CS, Mehta V, Singh A, Joshi MC, Narang V, Kaur K (2019) Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis. Intest Res 17:78–86

48 Suffredini AF, Noveck RJ (2014) Human endotoxin administration as an experimental model in drug development. Clin Pharmacol Ther 96:418–422

49 Sung J, Jeon H, Kim IH, Jeong HS, Lee J (2017) Anti-inflammatory effects of stearidonic acid mediated by suppression of NFkappaB and MAP-kinase pathways in macrophages. Lipids 52:781–787

50 Symonds EM, Nguyen KH, Harwood VJ, Breitbart M (2018) Pepper mild mottle virus: a plant pathogen with a greater purpose in (waste)water treatment development and public health management. Water Res 144:1–12

51 Tan ZX, Chen YH, Xu S, Qin HY, Wang H, Zhang C, Xu DX, Zhao H (2016) Calcitriol inhibits tumor necrosis factor alpha and macrophage inflammatory protein-2 during lipopolysaccharideinduced acute lung injury in mice. Steroids 112:81–87

52 Vuong LD, Nguyen QN, Truong VL (2019) Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells. Immunopharmacol Immunotoxicol 41:413–419

53 Wang CH, Rong MY, Wang L, Ren Z, Chen LN, Jia JF, Li XY, Wu ZB, Chen ZN, Zhu P (2014) CD147 up-regulates calcium-induced chemotaxis, adhesion ability and invasiveness of human neutrophils via a TRPM-7-mediated mechanism. Rheumatology (Oxford) 53:2288–2296

54 Wang H, Cui B, Li Q, Ding X, Li P, Zhang T, Yang X, Ji G, Zhang F (2018) The safety of fecal microbiota transplantation for Crohn’s disease: findings from a long-term study. Adv Ther 35:1935–1944

55 Wang JW, Wang YK, Zhang F, Su YC, Wang JY, Wu DC, Hsu WH (2019) Initial experience of fecal microbiota transplantation in gastrointestinal disease: a case series. Kaohsiung J Med Sci 35:566–571

56 Wu X, Dai M, Buch H, Bai J, Long W, Long C, Tang X, Tu H, Zhang R, Zhu C (2019) The recognition and attitudes of postgraduate medical students toward fecal microbiota transplantation: a questionnaire study. Therap Adv Gastroenterol 12:1756284819869144

57 Yates DT, Loest CA, Ross TT, Hallford DM, Carter BH, Limesand SW (2011) Effects of bacterial lipopolysaccharide injection on white blood cell counts, hematological variables, and serum glucose, insulin, and cortisol concentrations in ewes fed low- or highprotein diets. J Anim Sci 89:4286–4293

58 Zhang F, Luo W, Shi Y, Fan Z, Ji G (2012) Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 107:1755–1756

59 Zhang F, Cui B, He X, Nie Y, Wu K, Fan D, FMT-standardization Study Group (2018) Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell 9:462–473

60 Zhang F, Zhang T, Zhu H, Borody TJ (2019) Evolution of fecal microbiota transplantation in methodology and ethical issues. Curr Opin Pharmacol 49:11–16

61 Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB (2012) Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 55:1652–1658

62 Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB (2014) Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Can J Gastroenterol Hepatol 28:319–324